MCID: DBT009
MIFTS: 67

Diabetes Mellitus

Categories: Endocrine diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Diabetes Mellitus

MalaCards integrated aliases for Diabetes Mellitus:

Name: Diabetes Mellitus 12 74 29 54 6 44 15 17 71 32
Diabetes 6 42 3 15 39 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9351
ICD9CM 34 250
MeSH 44 D003920
NCIt 50 C2985
SNOMED-CT 67 267467004
UMLS 71 C0011847 C0011849

Summaries for Diabetes Mellitus

MedlinePlus : 42 Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes. Over time, having too much glucose in your blood can cause serious problems. It can damage your eyes, kidneys, and nerves. Diabetes can also cause heart disease, stroke and even the need to remove a limb. Pregnant women can also get diabetes, called gestational diabetes. Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Exercise, weight control and sticking to your meal plan can help control your diabetes. You should also monitor your blood glucose level and take medicine if prescribed. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, also known as diabetes, is related to type 2 diabetes mellitus and permanent neonatal diabetes mellitus, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Diabetes Mellitus is KCNJ11 (Potassium Inwardly Rectifying Channel Subfamily J Member 11), and among its related pathways/superpathways are MicroRNAs in cancer and Regulation of beta-cell development. The drugs Curcumin and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, pancreas and kidney.

Disease Ontology : 12 A glucose metabolism disease characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.

CDC : 3 Diabetes is a chronic (long-lasting) disease that affects how your body turns food into energy. There are three main types of diabetes: type 1, type 2, and gestational diabetes (diabetes while pregnant).

Novus Biologicals : 55 Diabetes is a disease in which the body does not produce or properly use insulin. There are four major types of diabetes: Type 1, Type 2, Gestational and Pre-Diabetes. Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune disease resulting when one's own immune system destroys insulin-producing beta cells in the pancreas. This causes the pancreas to produce little or no insulin. In type 2 diabetes, the body either does not produce enough insulin or beta cells ignore insulin. Gestational diabetes refers to high glucose levels caused by pregnancy. Pre-diabetes is a condition in which blood glucose levels are high, but not high enough for the diagnosis of type 2 diabetes.

Wikipedia : 74 Diabetes mellitus (DM), commonly known as diabetes, is a group of metabolic disorders characterized by a... more...

Related Diseases for Diabetes Mellitus

Diseases in the Diabetes Mellitus family:

Type 1 Diabetes Mellitus 2 Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus 3
Type 1 Diabetes Mellitus 4 Type 1 Diabetes Mellitus 5
Type 1 Diabetes Mellitus 7 Type 1 Diabetes Mellitus 8
Type 1 Diabetes Mellitus 11 Type 1 Diabetes Mellitus 13
Type 1 Diabetes Mellitus 12 Type 2 Diabetes Mellitus 2
Type 1 Diabetes Mellitus 15 Type 1 Diabetes Mellitus 6
Type 1 Diabetes Mellitus 10 Type 1 Diabetes Mellitus 17
Type 2 Diabetes Mellitus 3 Diabetes Mellitus, Congenital Autoimmune
Type 1 Diabetes Mellitus 18 Type 2 Diabetes Mellitus 4
Type 1 Diabetes Mellitus 19 Type 1 Diabetes Mellitus 20
Type 1 Diabetes Mellitus 21 Type 1 Diabetes Mellitus 22
Type 1 Diabetes Mellitus 23 Type 1 Diabetes Mellitus 24
Type 2 Diabetes 5 Rare Diabetes Mellitus Type 1
Rare Diabetes Mellitus Type 2 Rare Diabetes Mellitus

Diseases related to Diabetes Mellitus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3245)
# Related Disease Score Top Affiliating Genes
1 type 2 diabetes mellitus 34.7 WFS1 SPINK1 MIR17 KCNJ11 HNF1A GCK
2 permanent neonatal diabetes mellitus 34.3 WFS1 RFX6 KCNJ11 HNF1A GCK
3 maturity-onset diabetes of the young 34.0 WFS1 RFX6 KCNJ11 HNF1A GCK
4 neonatal diabetes 34.0 RFX6 KCNJ11 GCK
5 gestational diabetes 34.0 KCNJ11 HNF1A GCK
6 transient neonatal diabetes mellitus 33.9 RFX6 KCNJ11 GCK
7 maturity-onset diabetes of the young, type 1 33.5 KCNJ11 HNF1A GCK
8 hyperglycemia 33.4 MALAT1 KCNJ11 HNF1A GCK
9 maturity-onset diabetes of the young, type 2 33.4 WFS1 KCNJ11 HNF1A GCK
10 type 1 diabetes mellitus 11 33.3 HNF1A CELA2A
11 maturity-onset diabetes of the young, type 3 33.0 KCNJ11 HNF1A GCK
12 maturity-onset diabetes of the young, type 4 33.0 KCNJ11 HNF1A GCK
13 maturity-onset diabetes of the young, type 6 32.9 KCNJ11 HNF1A GCK
14 maturity-onset diabetes of the young, type 10 32.9 KCNJ11 GCK
15 pancreatic agenesis 32.8 RFX6 KCNJ11 GCK
16 glucose intolerance 32.7 KCNJ11 HNF1A GCK
17 maturity-onset diabetes of the young, type 8, with exocrine dysfunction 32.7 KCNJ11 GCK
18 maturity-onset diabetes of the young, type 7 32.7 KCNJ11 GCK
19 maturity-onset diabetes of the young, type 9 32.6 KCNJ11 GCK
20 insulinoma 32.3 WFS1 MEN1 HNF1A GCK
21 pancreatitis, hereditary 32.3 SPINK1 MIR99A MIR197
22 body mass index quantitative trait locus 11 32.3 MIR30E MIR17 MIR155 MIR140 KCNJ11 HNF1A
23 monogenic diabetes 32.1 KCNJ11 HNF1A GCK
24 lipoprotein quantitative trait locus 31.8 MIR17 MIR155 MIR145 MIR140 CELA2A CDKN2B-AS1
25 hyperinsulinemic hypoglycemia 31.7 MEN1 KCNJ11 HNF1A GCK
26 arteries, anomalies of 31.7 MIR30E MIR17 MIR155 MIR145 MIR140 MIR132
27 hypertension, essential 31.4 MIR30E MIR17 MIR155 MIR145 MEN1 KCNJ11
28 glucose metabolism disease 31.4 MIR17 MIR155 MIR140 KCNJ11 GCK
29 bile duct disease 31.3 MIR30E MIR17 MIR145 MIR140
30 cardiovascular system disease 31.2 MIR17 MIR155 MIR145 CDKN2B-AS1
31 renal cysts and diabetes syndrome 31.1 KCNJ11 HNF1A GCK
32 factitious disorder 31.1 KCNJ11 GCK
33 prostate disease 31.0 MIR99A MIR30E MIR17 MIR145 MIR140 MALAT1
34 pancreatic cancer 31.0 SPINK1 MIR99A MIR375 MIR17 MIR155 MIR145
35 pancreatic ductal adenocarcinoma 31.0 MIR375 MIR155 MIR145 MALAT1
36 rectum cancer 30.9 MIR99A MIR17 MIR145
37 pituitary adenoma 30.9 MIR197 MIR132 MEN1 MALAT1
38 colonic disease 30.9 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
39 pancreas, annular 30.8 SPINK1 RFX6
40 munchausen by proxy 30.8 KCNJ11 GCK
41 bladder cancer 30.7 MIR99A MIR30E MIR17 MIR145 MALAT1 CDKN2B-AS1
42 cervical cancer 30.7 MIR17 MIR155 MIR145 MALAT1 CDKN2B-AS1
43 maturity-onset diabetes of the young, type 13 30.7 KCNJ11 GCK
44 renal cell carcinoma, nonpapillary 30.6 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
45 hepatocellular carcinoma 30.6 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
46 glioma 30.6 MIR17 MIR140 MALAT1 CDKN2B-AS1
47 esophageal cancer 30.5 MIR375 MIR30E MIR145 MIR140 MALAT1 CDKN2B-AS1
48 myeloma, multiple 30.5 MIR17 MIR145 MIR140 MALAT1
49 biliary tract disease 30.5 MIR30E MIR17 MIR145 MIR140
50 pancreas disease 30.4 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140

Graphical network of the top 20 diseases related to Diabetes Mellitus:



Diseases related to Diabetes Mellitus

Symptoms & Phenotypes for Diabetes Mellitus

UMLS symptoms related to Diabetes Mellitus:


tremor, angina pectoris, equilibration disorder, symptoms

Drugs & Therapeutics for Diabetes Mellitus

Drugs for Diabetes Mellitus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 929)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
2
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
3
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568 5271565
4
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
5
Petrolatum Approved, Investigational Phase 4 8009-03-8
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
8
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
9
Empagliflozin Approved Phase 4 864070-44-0
10
Vorapaxar Approved Phase 4 618385-01-6
11
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
12
Ethanol Approved Phase 4 64-17-5 702
13
Sertraline Approved Phase 4 79617-96-2 68617
14
Atorvastatin Approved Phase 4 134523-00-5 60823
15
Fenofibrate Approved Phase 4 49562-28-9 3339
16
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
20
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
21
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
24
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
25
Ramipril Approved Phase 4 87333-19-5 5362129
26
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
27
Indapamide Approved Phase 4 26807-65-8 3702
28
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
29
Bosentan Approved, Investigational Phase 4 147536-97-8 104865
30
Sodium citrate Approved, Investigational Phase 4 68-04-2
31
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
32
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
33
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
34
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
35
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
36
Chlorzoxazone Approved Phase 4 95-25-0 2733
37
Tolbutamide Approved, Investigational Phase 4 64-77-7 5505
38
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
39
Thrombin Approved, Investigational Phase 4
40
Ziprasidone Approved Phase 4 146939-27-7 60854
41
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
42
Trandolapril Approved Phase 4 87679-37-6 5484727
43
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
44
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
45
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
46
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
47
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
48
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
49
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
50
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 The Effects of OMACOR on the LDL Sub-fraction in Korean Type 2 Diabetic Patients With Combined Hyperlipidemia Unknown status NCT00758927 Phase 4 Omega-3 acid 4 grams per day;Placebo control
2 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
3 Preventive Strategies of REnal Insufficiency in Patients With Diabetes Undergoing InterVENTion or Arteriography(PREVENT Trial) Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
4 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
5 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
6 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
7 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
8 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
9 A Pilot Study to Determine the Impact of Real-Time Continuous Glucose Monitoring (CGM) on Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
10 Efficacy and Safety of Empagliflozin Compared With Linagliptin in New-onset Diabetes Mellitus After Kidney Transplantation Unknown status NCT03642184 Phase 4 Empagliflozin;Linagliptin
11 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
12 Effects of SGLT2 Inhibitor on Markers of Inflammation, Atherosclerosis and Left Ventricular Strain in Diabetic Patients With Coronary Artery Disease Unknown status NCT03398577 Phase 4 Dapagliflozin 10 MG [Farxiga];Placebo Oral Tablet
13 A Prospective Single Blind Randomised Controlled Study to Compare the Outcomes of Patients With Diabetes and Clinically Non-infected Neuro-ischaemic and Neuropathic Foot Ulcers Treated With and Without Oral Antibiotics. Unknown status NCT01418456 Phase 4 antibiotics
14 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
15 Efficacy of Myo-inositol in Preventing Gestational Diabetes in High-risk Pregnant Women Unknown status NCT01511835 Phase 4 Folic Acid
16 Impact of Insulin Detemir Versus Insulin Glargine on Glycaemic Control and Metabolism During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4 Insulin glargine;Insulin detemir
17 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
18 Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography Unknown status NCT01023919 Phase 4
19 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
20 The Efficacy and Safety of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase 4 Inhibitor Added to Premix Insulin Injection Twice Daily in Uncontrolled Type 2 Diabetes Patients Unknown status NCT03458715 Phase 4 SGLT2 inhibitor (Empagliflozin 25 MG);DPP4 inhibitor (Linagliptin 5 MG)
21 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
22 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
23 The Effects of Empagliflozin on Functional and Structural Arterial Wall Characteristics Unknown status NCT03639545 Phase 4 Empagliflozin 25mg;Metformin;Empagliflozin/Metformin;Placebos
24 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
25 A Five Year, Prospective, Randomized, Blinded, Controlled Trial Comparing the Efficacy of a Modified Diabetes Prevention Protocol and the Standard Comprehensive Outpatient Care in Lowering the Incidence of New Onset Diabetes Among People Treated for Schizophrenia and Are at Risk to Develop Type II Diabetes Mellitus. Unknown status NCT00182494 Phase 4
26 Effect of Metformin as add-on Therapy on Glycemic Control and Other Diabetes-Related Outcomes in Type 1 Diabetic Patients:a Open-label,Self-control Study Unknown status NCT03590262 Phase 4 Metformin
27 A-One: A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone Unknown status NCT03313960 Phase 4 Afrezza plus One Drop | Premium
28 Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study) Unknown status NCT02577159 Phase 4 Dapagliflozin
29 To Compare the Efficacy and Safety Between Pioglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin and Placebo Control Group in Patients With Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
30 GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes Unknown status NCT03029351 Phase 4 Exenatide Extended Release for Inj Susp 2 MG;Placebos
31 Effects of Thyroid Hormone Treatment on Mitochondrial Function, Ectopic Fat Accumulation, Insulin Sensitivity and Brown Adipose Tissue in Type 2 Diabetes Mellitus Unknown status NCT01379170 Phase 4 Euthyrox (levothyroxine)
32 Organization Program of DiabEtes INsulIN ManaGement: An Open, Multi-center, Prospective, Randomized, 16-week, Controlled Clinical Study Unknown status NCT01338376 Phase 4 Scilin®M30
33 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
34 Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus Unknown status NCT02775253 Phase 4
35 Metabolism-independent Vascular Effects of the Dipetidylpeptidase-4-inhibitor Sitagliptin in Patients With Type 2 Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
36 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
37 A Randomized, Non-inferiority, Open-label Clinical Trial to Evaluate the Safety and Efficacy of GAcarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes in Chinese Unknown status NCT02605772 Phase 4 Acarbose;Metformin;Saxagliptin
38 Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes Unknown status NCT02526810 Phase 4 insulin lispro;Insulin Glargine
39 A Randomized, Double-blind, Active Control, Parallel Group, Exploratory Phase IV Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin in Patients With Inadequately Controlled Type2 Diabetes Mellitus in Metformin Only Treatment Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
40 Randomized, Long-Term Study About the Effects of Analogue Versus Human Insulin Based Regimens (Insulin Detemir and Aspart Versus NPH- and Regular Human Insulin) on Metabolic Control and Myocardial Function in People With Type 2 Diabetes. Unknown status NCT00747409 Phase 4 insulin aspart and detemir (NovoRapid, Levemir);human regular insulin and NPH insulin (Actrapid, Protaphne)
41 Effects of Sitagliptin On Markers of Bone Turnover in Patients With Type 2 Diabetes Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
42 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial Unknown status NCT02169570 Phase 4
43 Randomized, Open Prospective Study of the Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2 Unknown status NCT02719756 Phase 4 Metformin;Dapagliflozin;Metformin up-titration
44 Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes Unknown status NCT01240070 Phase 4
45 A Single Center, Open Label, Randomized Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes Unknown status NCT01185236 Phase 4 simvastatin/ezetimibe;atorvastatin 20mg
46 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
47 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
48 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
49 The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
50 A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR

Search NIH Clinical Center for Diabetes Mellitus

Inferred drug relations via UMLS 71 / NDF-RT 51 :


CHROMIUM PICOLINATE

Cochrane evidence based reviews: diabetes mellitus

Genetic Tests for Diabetes Mellitus

Genetic tests related to Diabetes Mellitus:

# Genetic test Affiliating Genes
1 Diabetes Mellitus 29

Anatomical Context for Diabetes Mellitus

MalaCards organs/tissues related to Diabetes Mellitus:

40
Endothelial, Pancreas, Kidney, Bone, Liver, Bone Marrow, Heart

Publications for Diabetes Mellitus

Articles related to Diabetes Mellitus:

(show top 50) (show all 54862)
# Title Authors PMID Year
1
The Prevention of Diabetes Mellitus. 61 42
33433568 2021
2
Lyumjev - a new insulin lispro for diabetes. 61 42
33429408 2020
3
Effects of Baduanjin on glucose and lipid metabolism in diabetic patients: A protocol for systematic review and meta-analysis. 42
33530160 2021
4
MicroRNA expression in human omental and subcutaneous adipose tissue. 47
19259271 2009
5
HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus. 61 54
19252740 2009
6
Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. 61 54
18060660 2008
7
Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. 54 61
17630927 2007
8
[The role of insulin resistance and resistin in pathogenesis of diabetes mellitus with special attention to diabetes in pregnancy]. 54 61
16363386 2005
9
Comparison of brain natriuretic peptide and left ventricular diastolic function determined by tissue Doppler in patients with diabetes mellitus, patients with hypertension without diabetes, and in healthy subjects. 54 61
15781031 2005
10
PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: Modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. 54 61
15654230 2005
11
A pancreatic islet-specific microRNA regulates insulin secretion. 47
15538371 2004
12
Diabetes mellitus in adults: association of HLA DRB1 and DQB1 diabetes risk alleles with GADab presence and C-peptide secretion. 54 61
15388265 2004
13
Diabetes mellitus in Tropical Chronic Pancreatitis Is Not Just a Secondary Type of Diabetes. 61 54
15258409 2004
14
Altered distribution of plasma PAF-AH between HDLs and other lipoproteins in hyperlipidemia and diabetes mellitus. 54 61
12867534 2003
15
Analysis of a non-functional HNF-1alpha (TCF1) mutation in Japanese subjects with familial type 1 diabetes. 61 54
11668618 2001
16
The length of the CTLA-4 microsatellite (AT)N-repeat affects the risk for type 1 diabetes. Diabetes Incidence in Sweden Study Group. 61 54
11092697 2000
17
Molecular genetics of diabetes mellitus in Chinese subjects: identification of mutations in glucokinase and hepatocyte nuclear factor-1alpha genes in patients with early-onset type 2 diabetes mellitus/MODY. 54 61
10588527 1999
18
Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. 61 54
9817917 1998
19
Molecular mimicry in diabetes mellitus: the homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie B-like enteroviruses and binds to the diabetes associated HLA-DR3 molecule. 61 54
9498628 1998
20
A case of type-1 diabetes mellitus formerly diagnosed as maturity-onset diabetes of the young (MODY) carrying suggestive MODY3 gene. 61 54
9483378 1997
21
The beta cell glucokinase promoter variant is an unlikely risk factor for diabetes mellitus. Diabetes Incidence Study in Sweden (DISS). 54 61
9267992 1997
22
Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. 61 54
9169397 1997
23
Evaluation of TAP1 polymorphisms with insulin dependent diabetes mellitus in Finnish diabetic patients. The Childhood Diabetes in Finland (DiMe) Study Group. 54 61
9129974 1997
24
Deletion of Gly723 in the insulin receptor substrate-1 of a patient with noninsulin-dependent diabetes mellitus. 61 54
8723689 1996
25
Dramatic increase in incidence of insulin dependent diabetes mellitus in Western Australia. 54 61
7935096 1994
26
Rury Holman: the science of diabetes and a life of trials. 61
33189183 2021
27
Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. 61
33403891 2021
28
Data-driven policies needed to turn the tide on diabetes. 61
33189185 2021
29
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. 61
33189186 2021
30
Effect of leech-centipede medicine on improving erectile function in diabetes-induced erectile dysfunction rats via PDE5 signalling pathway-related molecules. 61
33569974 2021
31
Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus. 61
33345632 2021
32
Inhibitory evaluation of Curculigo latifolia on α-glucosidase, DPP (IV) and in vitro studies in antidiabetic with molecular docking relevance to type 2 diabetes mellitus. 61
33249946 2021
33
The predictive value of diabetic retinopathy on subsequent diabetic nephropathy in patients with type 2 diabetes: a systematic review and meta-analysis of prospective studies. 61
33478336 2021
34
Case report: Giant pyonephrosis due to urolithiasis and diabetes. 61
33552917 2021
35
Pharmacological reflection of plants traditionally used to manage diabetes mellitus in Tanzania. 61
33358853 2021
36
Valorisation of kitul, an overlooked food plant: Phenolic profiling of fruits and inflorescences and assessment of their effects on diabetes-related targets. 61
33069534 2021
37
The Relationship Between Heavy Metal Exposure, Trace Element Level, and Monocyte to HDL Cholesterol Ratio with Gestational Diabetes Mellitus. 61
33219922 2021
38
Diabetes Type 1 Negatively Influences Leydig Cell Function in Rats, Which is Partially Reversible By Insulin Treatment. 61
33507237 2021
39
Cadmium exposure impairs pancreatic β-cell function and exaggerates diabetes by disrupting lipid metabolism. 61
33508533 2021
40
Critique of the "Comment" etitled "Pyrethroid exposure: Not so harmless after all" by Demeneix et al. (2020) published in the lancet diabetes endocrinology. 61
33412252 2021
41
Echocardiographic follow-up to right ventricular modifications in secondary pulmonary hypertension to diabetes in rats. 61
33349077 2021
42
Relationship Between Zinc Status and DNA Oxidative Damage in Patients with Type 2 Diabetes Mellitus. 61
32666431 2021
43
Unusual case presentation of fungal ball infection causing diabetes insipidus and seizure disorder. 61
33537110 2021
44
Placental pathology and neonatal outcomes in pre-eclampsia with gestational diabetes mellitus. 61
32627623 2021
45
Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan, China. 61
33289151 2021
46
Is the probable spillage of the lung surfactant dipalmitoylphosphatidylcholine the ultimate source of diabetes type 1? 61
33421610 2021
47
Impact of treatment of diabetic macular edema on visual impairment in people with diabetes mellitus in India. 61
33595499 2021
48
Commentary: Impact of treatment of diabetic macular edema on visual impairment in people with diabetes mellitus in India. 61
33595500 2021
49
An 'Ayurveda-Biology' platform for integrative diabetes management. 61
33181283 2021
50
Clinical Prediction Tool To Identify Adults With Type 2 Diabetes at Risk for Persistent Adverse Glycemia in Hospital. 61
33011129 2021

Variations for Diabetes Mellitus

ClinVar genetic disease variations for Diabetes Mellitus:

6 (show all 41)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HNF1A NM_000545.8(HNF1A):c.1139del (p.Val380fs) Deletion Pathogenic 916726 12:121434375-121434375 12:120996572-120996572
2 HNF1A NM_000545.8(HNF1A):c.1310-1G>A SNV Pathogenic 916727 12:121435276-121435276 12:120997473-120997473
3 WFS1 NM_006005.3(WFS1):c.1362_1377del (p.Pro453_Tyr454insTer) Deletion Pathogenic 916728 4:6302884-6302899 4:6301157-6301172
4 HNF1A NM_000545.6(HNF1A):c.812G>A (p.Arg271Gln) SNV Pathogenic 449403 rs779184183 12:121432065-121432065 12:120994262-120994262
5 HNF1A NM_000545.6(HNF1A):c.599G>A (p.Arg200Gln) SNV Pathogenic 381588 rs893256143 12:121431395-121431395 12:120993592-120993592
6 HNF1A NM_000545.8(HNF1A):c.824A>T (p.Glu275Val) SNV Pathogenic 918065 12:121432077-121432077 12:120994274-120994274
7 WFS1 NM_006005.3(WFS1):c.1839G>A (p.Trp613Ter) SNV Pathogenic 349320 rs143064649 4:6303361-6303361 4:6301634-6301634
8 WFS1 NM_006005.3(WFS1):c.1514G>A (p.Cys505Tyr) SNV Pathogenic 918063 4:6303036-6303036 4:6301309-6301309
9 WFS1 NM_006005.3(WFS1):c.817G>T (p.Glu273Ter) SNV Pathogenic 918066 4:6296872-6296872 4:6295145-6295145
10 WFS1 NM_001145853.1(WFS1):c.2015T>C SNV Pathogenic 918069
11 RFX6 NM_173560.4(RFX6):c.224-12A>G SNV Pathogenic 497 rs587776515 6:117198947-117198947 6:116877784-116877784
12 WFS1 NM_006005.3(WFS1):c.2020G>A (p.Gly674Arg) SNV Pathogenic 215394 rs200672755 4:6303542-6303542 4:6301815-6301815
13 KCNJ11 NM_000525.3(KCNJ11):c.601C>T (p.Arg201Cys) SNV Pathogenic 8668 rs80356625 11:17409038-17409038 11:17387491-17387491
14 KCNJ11 NM_000525.3(KCNJ11):c.685G>A (p.Glu229Lys) SNV Pathogenic 158683 rs587783673 11:17408954-17408954 11:17387407-17387407
15 KCNJ11 NM_000525.3(KCNJ11):c.964G>A (p.Glu322Lys) SNV Pathogenic 21203 rs193929355 11:17408675-17408675 11:17387128-17387128
16 KCNJ11 NM_000525.3(KCNJ11):c.988T>C (p.Tyr330His) SNV Pathogenic 158688 rs587783675 11:17408651-17408651 11:17387104-17387104
17 MEN1 NM_000244.3(MEN1):c.669+1del Deletion Pathogenic 374107 rs1057518903 11:64575362-64575362 11:64807890-64807890
18 CELA2A NM_033440.3(CELA2A):c.361G>A (p.Asp121Asn) SNV Pathogenic 633592 rs1352544800 1:15789885-15789885 1:15463390-15463390
19 CELA2A NM_033440.3(CELA2A):c.253C>A (p.Leu85Met) SNV Pathogenic 633593 rs558493952 1:15789253-15789253 1:15462758-15462758
20 CELA2A NM_033440.3(CELA2A):c.639+1G>C SNV Pathogenic 633594 rs752331004 1:15792640-15792640 1:15466145-15466145
21 CELA2A NM_033440.3(CELA2A):c.209C>T (p.Thr70Met) SNV Pathogenic 633595 rs372947070 1:15788135-15788135 1:15461640-15461640
22 WFS1 NM_006005.3(WFS1):c.1672C>T (p.Arg558Cys) SNV Pathogenic 198835 rs199946797 4:6303194-6303194 4:6301467-6301467
23 GCK NM_000162.5(GCK):c.772G>A (p.Gly258Ser) SNV Pathogenic 918070 7:44187340-44187340 7:44147741-44147741
24 SPINK1 NM_003122.4(SPINK1):c.194+2T>C SNV Pathogenic 132142 rs148954387 5:147207583-147207583 5:147828020-147828020
25 KCNJ11 NM_000525.3(KCNJ11):c.679G>A (p.Glu227Lys) SNV Pathogenic 158682 rs587783672 11:17408960-17408960 11:17387413-17387413
26 PMM2 NM_000303.3(PMM2):c.422G>A (p.Arg141His) SNV Likely pathogenic 7706 rs28936415 16:8905010-8905010 16:8811153-8811153
27 KCNJ11 NM_000525.3(KCNJ11):c.498C>G (p.Cys166Trp) SNV Likely pathogenic 158676 rs587783669 11:17409141-17409141 11:17387594-17387594
28 PMM2 NM_000303.3(PMM2):c.584A>G (p.His195Arg) SNV Likely pathogenic 812999 rs1596489887 16:8906908-8906908 16:8813051-8813051
29 WFS1 NM_006005.3(WFS1):c.961A>C (p.Thr321Pro) SNV Likely pathogenic 918064 4:6302483-6302483 4:6300756-6300756
30 INS-IGF2 NM_000207.3(INS):c.286T>C (p.Cys96Arg) SNV Likely pathogenic 918067 11:2181129-2181129 11:2159899-2159899
31 INS-IGF2 NM_000207.3(INS):c.174del (p.Glu59fs) Deletion Likely pathogenic 916729 11:2182028-2182028 11:2160798-2160798
32 HNF1A NM_000545.6(HNF1A):c.475C>T (p.Arg159Trp) SNV Likely pathogenic 429750 rs765432081 12:121426784-121426784 12:120988981-120988981
33 HNF1A NM_000545.8(HNF1A):c.404A>C (p.Asp135Ala) SNV Likely pathogenic 918061 12:121426713-121426713 12:120988910-120988910
34 HNF1A NM_000545.8(HNF1A):c.639C>G (p.Ile213Met) SNV Likely pathogenic 918062 12:121431435-121431435 12:120993632-120993632
35 WFS1 NM_006005.3(WFS1):c.2082G>C (p.Glu694Asp) SNV Uncertain significance 918068 4:6303604-6303604 4:6301877-6301877
36 KCNJ11 NM_000525.4(KCNJ11):c.463G>A SNV Uncertain significance 158675 rs587783668 11:17409176-17409176 11:17387629-17387629
37 HNF1A NM_000545.8(HNF1A):c.56C>T (p.Ser19Leu) SNV Uncertain significance 918071 12:121416627-121416627 12:120978824-120978824
38 ARMC9 NM_001352754.2(ARMC9):c.636G>C (p.Gln212His) SNV Uncertain significance 739322 rs201590882 2:232099950-232099950 2:231235237-231235237
39 KLF11 NM_003597.5(KLF11):c.1077G>A (p.Met359Ile) SNV Uncertain significance 330636 rs146486664 2:10188541-10188541 2:10048414-10048414
40 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro) SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468
41 ABCC8 NM_000352.6(ABCC8):c.1562G>A (p.Arg521Gln) SNV Uncertain significance 157683 rs368114790 11:17464335-17464335 11:17442788-17442788

Copy number variations for Diabetes Mellitus from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 110220 17 3154257 3410803 Deletion HNF1B Diabetes mellitus
2 110369 17 31923035 33323544 Deletion HNF1B Diabetes mellitus
3 110541 17 33120546 33179209 Deletion HNF1B Diabetes mellitus
4 203632 1 158846514 158883705 Rearrangement SLAMF1 Diabetes mellitus
5 225144 7 43300000 45400000 Gain or loss GCK Diabetes mellitus

Expression for Diabetes Mellitus

Search GEO for disease gene expression data for Diabetes Mellitus.

Pathways for Diabetes Mellitus

GO Terms for Diabetes Mellitus

Cellular components related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 SPINK1 MIR99A MIR375 MIR30E MIR197 MIR17

Biological processes related to Diabetes Mellitus according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.83 MIR17 MIR155 MIR140 MIR132 CDKN2B-AS1
2 cellular response to hypoxia GO:0071456 9.67 MIR17 MIR155 MIR140 MALAT1
3 negative regulation of interleukin-6 production GO:0032715 9.65 MIR155 MIR140 MIR132
4 negative regulation of sprouting angiogenesis GO:1903671 9.58 MIR375 MIR30E MIR17
5 glucose homeostasis GO:0042593 9.56 WFS1 RFX6 HNF1A GCK
6 positive regulation of macrophage activation GO:0043032 9.54 MIR155 MIR145
7 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.52 MIR17 MIR155
8 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.51 MIR17 MIR155
9 negative regulation of vascular endothelial growth factor production GO:1904046 9.5 MIR17 MIR140 MIR134
10 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.49 MIR17 MIR155
11 type B pancreatic cell differentiation GO:0003309 9.46 RFX6 MEN1
12 regulation of insulin secretion GO:0050796 9.46 RFX6 KCNJ11 GCK CELA2A
13 miRNA mediated inhibition of translation GO:0035278 9.35 MIR17 MIR155 MIR145 MIR134 MIR132
14 gene silencing by miRNA GO:0035195 9.32 MIR99A MIR375 MIR30E MIR197 MIR17 MIR155

Molecular functions related to Diabetes Mellitus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR99A MIR30E MIR17 MIR155 MIR145 MIR140
2 RNA polymerase II complex binding GO:0000993 9.13 MIR375 MIR145 MIR140

Sources for Diabetes Mellitus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....